Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (5640)	1/23/2020 2:18:04 PM
From: Wildbiftek	Respond to of 5665

There's a nice, almost year-long cup and handle forming here. I think this may settle into a higher range now that there's some clarity for funding into a states side launch alongside the low bar, regulatory clarity for approval we got in December. Who knows if the book runners shorted the stock in december in anticipation of this secondary, but they get to cover some of that in the secondary and the rest of the shorts appear to be squeezed as a result. It looks like JPM who has the only negative rating on the stock (despite their report on IMGN reading quite positively) was the primary bookrunner for their first secondary in June of '18 when they had a buy rating on the stock. This time they were left out: the book runners were Jeffries, Cowen and William Blair whose analysts have outperform ratings on the stock except for Jeffries with a neutral. I think JPM will be forced to change their tune with this fresh infusion of cash along side a relatively clear path to commercialization.

To: Gary Mohilner who wrote (5640)	12/14/2020 12:38:37 PM
From: Area51	Respond to of 5665

IMGN getting some impressive action today. I think you have to like it if it can stay over $7? 12/4/2020: Cowen analyst John Scott reiterated an Outperform rating and on Immunogen Inc. (NASDAQ: IMGN) and highlighted the company as his Best Biotech Idea for 2021. What the street appears to be missing is the de-risked first-in-class potential of lead drugmirvetuximab. https://www.streetinsider.com/Analyst+Comments/Immunogen+Inc.+(IMGN)+Names+Top+Biotech+Idea+for+2021+at+Cowen/17682898.html